ICON-7 and GOG-218 Bevacizumab Regimens for Advanced Ovarian Cancer
Both ICON-7 and GOG-218 are bevacizumab-containing regimens combined with carboplatin and paclitaxel chemotherapy for advanced ovarian cancer, but they differ critically in bevacizumab dosing (7.5 mg/kg vs 15 mg/kg) and treatment duration (12 vs 15 months). These regimens represent the two validated approaches for incorporating bevacizumab into first-line ovarian cancer treatment, though neither is universally recommended due to modest benefits and quality-of-life concerns 1, 2, 3.
ICON-7 Regimen
The ICON-7 protocol uses lower-dose bevacizumab over a shorter duration 1, 2, 3, 4:
- Paclitaxel 175 mg/m² IV over 3 hours + Carboplatin AUC 5-6 IV + Bevacizumab 7.5 mg/kg IV on Day 1
- Repeat every 3 weeks for 5-6 cycles (concurrent phase)
- Continue bevacizumab 7.5 mg/kg alone every 3 weeks for up to 12 additional cycles (maintenance phase)
- Total treatment duration: approximately 12 months (18 cycles total)
ICON-7 Patient Population and Outcomes
ICON-7 enrolled a broader population including high-risk early-stage disease (FIGO stage I-IIa with grade 3 or clear cell histology) and advanced disease (stage IIb-IV), not just those with macroscopic residual disease 4. The trial showed improved progression-free survival but no overall survival benefit in the general population 5. However, a predefined high-risk subgroup (stage III with >1 cm residual disease or stage IV) demonstrated both PFS and OS improvement 4.
GOG-218 Regimen
The GOG-218 protocol uses higher-dose bevacizumab over longer duration 1, 2, 3, 1:
- Paclitaxel 175 mg/m² IV over 3 hours + Carboplatin AUC 6 IV on Day 1 for 6 cycles (every 3 weeks)
- Starting Day 1 of cycle 2: add Bevacizumab 15 mg/kg IV every 3 weeks
- Continue bevacizumab 15 mg/kg alone every 3 weeks for up to 22 total cycles (maintenance phase)
- Total treatment duration: approximately 15 months
GOG-218 Patient Population and Outcomes
GOG-218 enrolled only patients with stage III-IV disease with macroscopic residual disease after surgery 4. The trial demonstrated improved PFS (median 14.1 vs 10.3 months) but no overall survival benefit 1, 6. Notably, bevacizumab was not given during cycle 1 of chemotherapy in GOG-218, distinguishing it from ICON-7 1.
Critical Differences Between Regimens
| Parameter | ICON-7 | GOG-218 |
|---|---|---|
| Bevacizumab dose | 7.5 mg/kg | 15 mg/kg |
| Bevacizumab start | Cycle 1, Day 1 | Cycle 2, Day 1 |
| Total duration | ~12 months (18 cycles) | ~15 months (22 cycles) |
| Carboplatin AUC | 5-6 | 6 |
| Patient population | Broader (includes high-risk early stage) | Restricted (stage III-IV with residual disease) |
Clinical Application and Caveats
The NCCN guidelines list both regimens as Category 2B or Category 3 recommendations, reflecting significant panel disagreement about routine bevacizumab use in first-line ovarian cancer 1, 3, 1. The controversy stems from:
- No overall survival benefit in unselected populations 1, 5
- Quality-of-life decrements during maintenance therapy 7: ICON-7 showed a 6.4-point lower global QoL score at week 54 with bevacizumab (p<0.0001), which is clinically significant
- Serious toxicity risks: 2-3% risk of gastrointestinal perforation/fistula 1
- High cost without clear survival advantage 1
When to Consider These Regimens
Bevacizumab should be prioritized for high-risk patients with poor prognostic features 4:
- Stage IV disease
- Stage III with suboptimal debulking (>1 cm residual disease)
- Poor tumor chemosensitivity (unfavorable KELIM score <1.0) 8
In the ICON-7 high-risk subgroup, bevacizumab improved OS (restricted mean survival 39.3 vs 34.5 months, p=0.03) 5. Similarly, GOG-218 validation studies showed greatest benefit in patients with high-risk disease and unfavorable chemosensitivity (PFS HR 0.64, OS HR 0.79) 8.
Important Safety Considerations
Bevacizumab must be withheld for 6 weeks before interval debulking surgery to allow adequate wound healing 2. This is particularly critical in the neoadjuvant setting, where bevacizumab use remains controversial and increases gastrointestinal perforation risk 9, 10.
The European Medicines Agency licensed bevacizumab at 15 mg/kg (GOG-218 dose), not the 7.5 mg/kg ICON-7 dose 4, though both regimens remain in clinical use depending on institutional preference and patient risk stratification.